Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors

27 Mar 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology, Volume 44, Issue 14 , Page 1337-1348, May 2026.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 27 Mar 2026. The item focuses on Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors. Open the detail page to review the full original feed content.